On September 24, 2026, Teppei Sakano, Board Director of Cartanova, took the stage to deliver a presentation at the World Cancer Congress 2026 held in Hong Kong.

This session was held under the theme of "Integrating AMR, Digital Transformation and Behavioral Science in Cancer Care."

Joining experts from the World Health Organization (WHO) and other international leaders, Mr. Sakano presented on the topic "FUTURE SOLUTIONS: GENERATIVE AI & AMR DIAGNOSTICS."

In his presentation, he highlighted the critical importance of addressing infection risks and Antimicrobial Resistance (AMR) in cancer care. He introduced cutting-edge technological approaches to building a safer healthcare environment by leveraging DX and Generative AI, drawing on practical implementation cases in Ukraine.

Cartanova remains committed to contributing to AMR countermeasures—a major global public health threat—and enhancing the quality of cancer care through the provision of medical DX and advanced technologies.

Session Overview

• Date: September 24, 2026

• Venue: Hong Kong Convention and Exhibition Centre (HKCEC)

• Session Theme: Integrating AMR, Digital Transformation and Behavioral Science in Cancer Care

• Presentation Title: FUTURE SOLUTIONS: GENERATIVE AI & AMR DIAGNOSTICS

Speakers

• Dr. André Ilbawi (Team Lead for Cancer Control, WHO)

• Dr. Asem H. Mansour (CEO & Director General, King Hussein Cancer Center)

• Prof. Dr. Murallitharan Munisamy (Managing Director, National Cancer Society of Malaysia)

• Teppei Sakano (Board Director, Cartanova / Board Director, Asia Cancer Forum)

• Chair: Dr. Masaru Iwasaki (Board Director, Asia Cancer Forum)

• Organiser: Dr. Norie Kawahara (Representative Director, Asia Cancer Forum)

CartaNova had the honor of delivering a presentation at the Military Medicine Research Unit of the Japan Ground Self-Defense Force (JGSDF), led by Colonel Machiko Kawasaki.

The presentation was attended by around 40 to 50 leaders and personnel from the medical division, including the Commander of the NBC Medical Unit and the Vice Commandant of the JGSDF Medical School.

Focusing on recent case studies from Ukraine,the session focused on the critical importance of Antimicrobial Resistance (AMR) countermeasures in military operational environments and wartime situations. Drawing on international data and real-world case studies, we discussed the challenges and implementation of Antimicrobial Stewardship Programs (ASP) during conflicts and emergencies.

During the Q&A segment, we engaged in a highly dynamic discussion with practical and insightful questions from the audience, highlighting the strong commitment and awareness regarding AMR threats in tactical and disaster medicine.

CartaNova remains dedicated to addressing the global threat of AMR by offering expertise and supporting initiatives across clinical, public health, and defense medicine sectors.

Through MOUs and ongoing partnerships with hospitals, universities, and public institutions across Ukraine, CartaNova Inc. is expanding its network for the implementation of NovaID.

By working closely with local healthcare professionals and institutional partners, we aim to adapt NovaID to local clinical needs and support its implementation across diverse healthcare settings.

CartaNova’s network of collaborating institutions across Ukraine.

Dr. Olha Izmailova with healthcare professionals at Dobrobut Clinic as part of ongoing collaboration on the implementation of NovaID.

We are pleased to announce that our project has been selected for the Ministry of Economy, Trade and Industry (METI)’s “FY2026 Subsidy Program for the International Expansion of the Healthcare Industry,” administered by Medical Excellence JAPAN (MEJ).

https://medicalexcellencejapan.org/common/img/all/pdf/R8hojo_saitakulist.pdf

• Subsidy Program: FY2026 Subsidy Program for the International Expansion of the Healthcare Industry

• Selected Project: Basic Survey Project for the Commercialization of “NovaID,” an AI-Powered Healthcare Support Service for Antimicrobial Resistance (AMR) in East Africa (Rwanda and Kenya)

• Target Region: East Africa (Rwanda and Kenya)

• Managing Organization: Medical Excellence JAPAN (MEJ)

Through this study, we will promote the commercialization and local deployment of “NovaID,” an AI-powered healthcare support service, to help address antimicrobial resistance (AMR) challenges in Rwanda and Kenya.